Skip to main content
. Author manuscript; available in PMC: 2020 Aug 1.
Published in final edited form as: Clin Cancer Res. 2019 Oct 18;26(3):581–587. doi: 10.1158/1078-0432.CCR-19-0471

Table 3.

Adverse events

Adverse Event (N=59) Grade 2 Grade 3 Grade 4 Total Grade 3 and 4
Anemia 36 14 0 14(24%)
Hypertriglyceridemia 14 7 1 8(15%)
Hyperglycemia 15 5 0 5 (9%)
Hyponatremia 0 4 0 4 (7%)
Fatigue 17 3 0 3 (6%)
Thrombocytopenia 4 3 0 3 (6%)
Abdominal pain 11 2 0 2 (4%)
Mucositis oral 13 2 0 2 (4%)
Infection 3 2 0 2 (4%)
Elevated liver function test 4 2 0 2 (4%)
Pain 4 2 0 2 (4%)